Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Olschewski, H.
Pulmonary hypertension: the future has begun
Med Klin (Munich). 2006; 101(4):328-333 Doi: 10.1007/s00063-006-1042-8
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Olschewski Horst
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: In recent years, pulmonary hypertension got into the focus of research due to the development of efficacious medications and the discovery of important pathologic mechanisms of disease. Currently, prostanoids, endothelin receptor antagonists and phosphodiesterase 5 inhibitors are the most important substance groups used for treatment. Substances that are emerging in tumor therapy (tyrosine kinase inhibitors, epidermal growth factor [EGF] und platelet-derived growth factor [PDGF] receptor blockers), vasoactive intestinal peptide (VIP), rho-kinase inhibitors and targeted drugs for endothelial dysfunction will be evaluated as future drugs for pulmonary hypertension.Improving early diagnosis of pulmonary hypertension will be an important task in the future. Both the development of diagnostic methods with increased sensitivity and specificity and a broad awareness program will be necessary to achieve this goal.
Find related publications in this database (using NLM MeSH Indexing): Animals -; Disease Models, Animal -; Drug Therapy, Combination -; Endothelium, Vascular - physiopathology; Forecasting - physiopathology; Humans - physiopathology; Hypertension, Pulmonary - classification; Phosphodiesterase Inhibitors - administration and dosage; Prostaglandins - administration and dosage; Protein-Tyrosine Kinases - antagonists and inhibitors; Pulmonary Artery - pathology; Rats - pathology; Receptor, Epidermal Growth Factor - antagonists and inhibitors; Receptors, Endothelin - antagonists and inhibitors; Receptors, Platelet-Derived Growth Factor - antagonists and inhibitors; Sensitivity and Specificity - antagonists and inhibitors; Smoking - adverse effects; Time Factors - adverse effects
Find related publications in this database (Keywords): pulmonary arterial hypertension; pulmonary hypertension; endothelin receptor antagonist; phosphodiesterase 5 inhibitor; prostanoid; tyrosine kinase inhibitor; EGF receptor blocker; PDGF receptor blocker